Medtronic Vascular Sales Remain Steady Despite Cypher Competition
This article was originally published in The Gray Sheet
Executive Summary
Myocardial cell replacement is among therapies Medtronic's vascular unit is striving to develop to curb reliance on coronary stent sales
You may also be interested in...
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
Medtronic Biotech Presence: “Pawn Or Rook?” Is VP Oesterle’s Challenge
Biologics delivery to aid organ restoration is a frontier that will permit Medtronic to advance beyond its core strengths in electromechanical implants, according to Senior VP-Medicine & Technology Stephen Oesterle